Developer docs
API playgroundTry for free, no card

Search company profiles

Remidio

Full company profile

uuid00hhunr

Namestring
Remidio
Legal namestring
Remidio Inc.
Websiteurl
remidio.us
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Remidio is an Indian-founded medical technology company (founded 2011) that develops portable, AI-assisted ophthalmic imaging devices and a cloud-connected teleophthalmology platform. Its product portfolio centers on handheld, battery-powered, non-mydriatic fundus cameras (InstaFOP FOP NM-10, InstaZ), supplemented by a portable digital slit lamp (InstaPSL), a handheld autorefractor (InstaRef R20), a handheld corneal topographer (InstaKC), and an attachment module (AIM) that digitizes existing slit lamps from multiple manufacturers. All devices feed into Remidio Connect, a HIPAA-, ISO 27001-, ISO 27017-, SOC 2 Type 2-, and GDPR-compliant cloud platform with DICOM/EMR/PACS integration, AI-powered clinical decision support (including Medios AI for diabetic retinopathy screening), and optional 24/7 teleophthalmology specialist services.

The company targets non-specialist healthcare settings — primary care providers, home care agencies, rural and mission clinics, emergency departments, and eye care specialists — where traditional ophthalmic equipment is too bulky, expensive, or operator-dependent. Go-to-market is direct enterprise field sales with quote-based, multi-year contracts; the company sells hardware, recurring cloud subscriptions, and managed telehealth services. As of December 2025, the FOP NM-10 received FDA 510(k) clearance, enabling US commercial deployment through Remidio Inc. (Glen Allen, Virginia), while the global headquarters remains in India. Devices are reported to have screened more than 16 million people across 55+ countries, with the company holding granted patents in India, the US, EU, Japan, China, and South Africa and 20+ peer-reviewed publications validating clinical performance.

Short descriptiontext

Remidio is an Indian-founded medtech company that builds portable, AI-assisted eye imaging devices (handheld fundus cameras, slit lamps, autorefractors, corneal scanners) and a cloud teleophthalmology platform for primary care, home care, emergency, rural, and eye care settings globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGlen Allen, United States
HQ citystring
Glen Allen
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
portable fundus cameras, handheld ophthalmic imaging, teleophthalmology platform, diabetic retinopathy screening, AI retinal diagnostics
Industry2 codes
PRIMARYHLAHAJAN
Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLALAGAL
Ophthalmology & Vision Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Ophthalmic Goods Manufacturing339115
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Optical Instruments & Lenses3827
Product category
Ophthalmic Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Hardware Sales
TypeHardware Sales
Description

Sale of portable eye imaging devices including handheld fundus cameras, corneal scanners, autorefractors, and slit lamps. Devices are sold directly to healthcare organizations with quote-based pricing.

remidio.us
2Cloud Platform and Software Services
TypeSubscription Recurring
Description

Remidio Connect cloud platform for image storage, teleophthalmology consultations, and clinical decision support. May include subscription-based pricing for managed telehealth services with 24/7 eye care providers.

3Enterprise/Telehealth Services
TypeManaged Services
Description

Fully managed teleophthalmology services with real-time access to licensed on-call eye care specialists. Provided as optional 24/7 service for when internal resources are unavailable.

remidio.us
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise healthcare pricing - quote-based
ModelOtherBilling cadenceMulti-year contract
Notes

No specific pricing tiers published. Contact sales for device quotes and enterprise agreements. Both Medicare and commercial insurance reimbursement available for fundus photography with interpretation.

remidio.us
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1InstaFOP
Description

Handheld Fundus Camera product line for retinal imaging

remidio.us
+7 more records
Core offering1 text field

Remidio designs, manufactures, and sells portable, FDA-cleared ophthalmic imaging devices — including handheld fundus cameras, portable slit lamps, autorefractors, and corneal scanners — along with the Remidio Connect cloud-based teleophthalmology platform. Its products enable point-of-care retinal, anterior segment, refractive, and corneal imaging without dilation, with AI-assisted clinical decision support, and are sold to healthcare organizations such as primary care providers, home care agencies, emergency departments, rural/mission programs, and eye care specialists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Average length of stay reduced by ~50% when fundus imaging available in ER
+3 more records
Product overview1 text field

Remidio offers a portfolio of FDA-cleared portable eye imaging devices designed for point-of-care screening across clinical settings. The product line centers on the InstaFOP and InstaZ fundus cameras for retinal imaging, complemented by the InstaPSL portable slit lamp for anterior segment imaging, InstaRef R20 autorefractor for refraction, and InstaKC corneal scanner for keratoconus detection. The Remidio Connect Cloud Platform serves as the unifying software layer, enabling image storage, AI-powered clinical decision support, and teleophthalmology workflows. The Anterior Imaging Module digitizes existing slit lamps, while the InstaEyeClinic Bag bundles multiple devices for mobile and outreach eye care delivery.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeOthers
Description

Bill Gates featured Remidio's FDA-cleared Fundus on Phone device in a LinkedIn post, highlighting its ability to detect early signs of conditions like high blood pressure and gestational diabetes, and its potential to reduce stillbirths and improve maternal healthcare globally. This endorsement serves as a significant credibility boost and potential pathway to Gates Foundation partnerships for global health initiatives.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Eyenuk develops EyeArt AI for autonomous diabetic retinopathy screening, used with various fundus cameras including handheld devices. It is an emerging peer at the intersection of AI screening software and portable retinal imaging, with overlapping customers and a complementary go-to-market.

TypeDirect peer
Description

Topcon is a leading global manufacturer of ophthalmic imaging devices including fundus cameras and OCT systems. It is a direct peer to Remidio in retinal/retinal-imaging devices for primary care and specialty eye care, though Topcon's portfolio is broader and more established in US hospital channels.

TypeDirect peer
Description

Nidek manufactures ophthalmic diagnostic equipment including fundus cameras, autorefractors, and slit lamps. It is a direct peer across Remidio's product categories (fundus, refraction, anterior imaging) with established global distribution.

TypeEmerging player
Description

Digital Diagnostics develops autonomous AI for diabetic retinopathy screening (LumineticsCore, formerly IDx-DR), the first FDA-authorized autonomous AI diagnostic. It is an emerging peer in the AI-screening software layer that pairs with fundus cameras like Remidio's.

TypeDirect peer
Description

Forus Health is an India-based innovator behind the 3nethra series of handheld fundus cameras used in vision screening programs. It is a direct peer in portable fundus imaging for primary care and rural screening and competes for similar emerging-market screening contracts.

6Carl Zeiss Meditec
TypeDirect peer
Description

Carl Zeiss Meditec manufactures ophthalmic diagnostic devices including fundus cameras, OCT, and perimeters. It is a direct competitor in ophthalmic imaging hardware and digital health, with strong incumbent relationships across US hospital and specialty practices where Remidio is now entering.

TypeDirect peer
Description

Heidelberg Engineering specializes in diagnostic imaging for ophthalmology including Spectralis OCT and confocal fundus imaging systems. It is a direct peer in advanced retinal imaging used by ophthalmologists and hospital eye departments.

TypeDirect peer
Description

Optomed is a Finland-based medical device company specializing in handheld fundus cameras and AI-powered screening software for diabetic retinopathy. It is the closest peer to Remidio in form factor (handheld fundus camera) and target use case (primary-care screening).

TypeDirect peer
Description

icare (acquired Centervue) markets the Eidon ultra-widefield confocal fundus imaging system. It is a direct peer in the fundus-imaging category serving both specialty clinics and emerging teleophthalmology workflows.

TypeBroad incumbent
Description

Canon Eye Care is a broad incumbent in retinal imaging through its CX-1 hybrid and CR-2 digital retinal cameras. It overlaps with Remidio's fundus-imaging offerings but is part of Canon's much larger medical and consumer imaging portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Remidio

Ophthalmic Medical Devicesremidio.us

Remidio is an Indian-founded medtech company that builds portable, AI-assisted eye imaging devices (handheld fundus cameras, slit lamps, autorefractors, corneal scanners) and a cloud teleophthalmology platform for primary care, home care, emergency, rural, and eye care settings globally.

What Remidio does

Remidio is an Indian-founded medical technology company (founded 2011) that develops portable, AI-assisted ophthalmic imaging devices and a cloud-connected teleophthalmology platform. Its product portfolio centers on handheld, battery-powered, non-mydriatic fundus cameras (InstaFOP FOP NM-10, InstaZ), supplemented by a portable digital slit lamp (InstaPSL), a handheld autorefractor (InstaRef R20), a handheld corneal topographer (InstaKC), and an attachment module (AIM) that digitizes existing slit lamps from multiple manufacturers. All devices feed into Remidio Connect, a HIPAA-, ISO 27001-, ISO 27017-, SOC 2 Type 2-, and GDPR-compliant cloud platform with DICOM/EMR/PACS integration, AI-powered clinical decision support (including Medios AI for diabetic retinopathy screening), and optional 24/7 teleophthalmology specialist services.

The company targets non-specialist healthcare settings — primary care providers, home care agencies, rural and mission clinics, emergency departments, and eye care specialists — where traditional ophthalmic equipment is too bulky, expensive, or operator-dependent. Go-to-market is direct enterprise field sales with quote-based, multi-year contracts; the company sells hardware, recurring cloud subscriptions, and managed telehealth services. As of December 2025, the FOP NM-10 received FDA 510(k) clearance, enabling US commercial deployment through Remidio Inc. (Glen Allen, Virginia), while the global headquarters remains in India. Devices are reported to have screened more than 16 million people across 55+ countries, with the company holding granted patents in India, the US, EU, Japan, China, and South Africa and 20+ peer-reviewed publications validating clinical performance.

Remidio firmographics

Firmographics
Name
Remidio
Legal name
Remidio Inc.
Website
https://remidio.us
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Remidio is an Indian-founded medtech company that builds portable, AI-assisted eye imaging devices (handheld fundus cameras, slit lamps, autorefractors, corneal scanners) and a cloud teleophthalmology platform for primary care, home care, emergency, rural, and eye care settings globally.
Ownership category
akta.pro rank

Remidio industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAHAJAN
Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLALAGAL
Ophthalmology & Vision Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Portable fundus cameras
  • Handheld ophthalmic imaging
  • Teleophthalmology platform
  • Diabetic retinopathy screening
  • AI retinal diagnostics

Where Remidio is headquartered

Location

Headquarters

HQ city
Glen Allen
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Remidio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Medical Device Hardware Sales: Sale of portable eye imaging devices including handheld fundus cameras, corneal scanners, autorefractors, and slit lamps. Devices are sold directly to healthcare organizations with quote-based pricing.
  2. Cloud Platform and Software Services: Remidio Connect cloud platform for image storage, teleophthalmology consultations, and clinical decision support. May include subscription-based pricing for managed telehealth services with 24/7 eye care providers.
  3. Enterprise/Telehealth Services: Fully managed teleophthalmology services with real-time access to licensed on-call eye care specialists. Provided as optional 24/7 service for when internal resources are unavailable.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise healthcare pricing - quote-based

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Remidio product offering

Product offering

Core offering

Remidio designs, manufactures, and sells portable, FDA-cleared ophthalmic imaging devices — including handheld fundus cameras, portable slit lamps, autorefractors, and corneal scanners — along with the Remidio Connect cloud-based teleophthalmology platform. Its products enable point-of-care retinal, anterior segment, refractive, and corneal imaging without dilation, with AI-assisted clinical decision support, and are sold to healthcare organizations such as primary care providers, home care agencies, emergency departments, rural/mission programs, and eye care specialists.

Product overview

Remidio offers a portfolio of FDA-cleared portable eye imaging devices designed for point-of-care screening across clinical settings. The product line centers on the InstaFOP and InstaZ fundus cameras for retinal imaging, complemented by the InstaPSL portable slit lamp for anterior segment imaging, InstaRef R20 autorefractor for refraction, and InstaKC corneal scanner for keratoconus detection. The Remidio Connect Cloud Platform serves as the unifying software layer, enabling image storage, AI-powered clinical decision support, and teleophthalmology workflows. The Anterior Imaging Module digitizes existing slit lamps, while the InstaEyeClinic Bag bundles multiple devices for mobile and outreach eye care delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • InstaFOP: Handheld Fundus Camera product line for retinal imaging
  • InstaPSL
  • InstaRef
  • InstaZ
  • InstaKC
  • InstaEyeClinic
  • Anterior Imaging Module (AIM)
  • Remidio Connect

Quantifiable outcome

  • Average length of stay reduced by ~50% when fundus imaging available in ER
  • +3 more outcomes

Companies that use Remidio

Customer profile

Named customers14 records

Segments5 records

Ideal customer profiles2 records

Remidio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature7 records

Remidio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Bill & Melinda Gates FoundationflagshipOthersBill Gates featured Remidio's FDA-cleared Fundus on Phone device in a LinkedIn post, highlighting its ability to detect early signs of conditions like high blood pressure and gestational diabetes, and its potential to reduce stillbirths and improve maternal healthcare globally. This endorsement serves as a significant credibility boost and potential pathway to Gates Foundation partnerships for global health initiatives.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Remidio competitors and assessment

Company assessment

Emerging players

  • Eyenuk: Eyenuk develops EyeArt AI for autonomous diabetic retinopathy screening, used with various fundus cameras including handheld devices. It is an emerging peer at the intersection of AI screening software and portable retinal imaging, with overlapping customers and a complementary go-to-market.
  • Digital Diagnostics (formerly IDx-DR): Digital Diagnostics develops autonomous AI for diabetic retinopathy screening (LumineticsCore, formerly IDx-DR), the first FDA-authorized autonomous AI diagnostic. It is an emerging peer in the AI-screening software layer that pairs with fundus cameras like Remidio's.

Direct peers

  • Topcon Healthcare: Topcon is a leading global manufacturer of ophthalmic imaging devices including fundus cameras and OCT systems. It is a direct peer to Remidio in retinal/retinal-imaging devices for primary care and specialty eye care, though Topcon's portfolio is broader and more established in US hospital channels.
  • Nidek: Nidek manufactures ophthalmic diagnostic equipment including fundus cameras, autorefractors, and slit lamps. It is a direct peer across Remidio's product categories (fundus, refraction, anterior imaging) with established global distribution.
  • Forus Health: Forus Health is an India-based innovator behind the 3nethra series of handheld fundus cameras used in vision screening programs. It is a direct peer in portable fundus imaging for primary care and rural screening and competes for similar emerging-market screening contracts.
  • Carl Zeiss Meditec: Carl Zeiss Meditec manufactures ophthalmic diagnostic devices including fundus cameras, OCT, and perimeters. It is a direct competitor in ophthalmic imaging hardware and digital health, with strong incumbent relationships across US hospital and specialty practices where Remidio is now entering.
  • Heidelberg Engineering: Heidelberg Engineering specializes in diagnostic imaging for ophthalmology including Spectralis OCT and confocal fundus imaging systems. It is a direct peer in advanced retinal imaging used by ophthalmologists and hospital eye departments.
  • Optomed: Optomed is a Finland-based medical device company specializing in handheld fundus cameras and AI-powered screening software for diabetic retinopathy. It is the closest peer to Remidio in form factor (handheld fundus camera) and target use case (primary-care screening).
  • icare (formerly Centervue / Eidon): icare (acquired Centervue) markets the Eidon ultra-widefield confocal fundus imaging system. It is a direct peer in the fundus-imaging category serving both specialty clinics and emerging teleophthalmology workflows.

Broad incumbents

  • Canon Eye Care: Canon Eye Care is a broad incumbent in retinal imaging through its CX-1 hybrid and CR-2 digital retinal cameras. It overlaps with Remidio's fundus-imaging offerings but is part of Canon's much larger medical and consumer imaging portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Remidio social profiles

Digital presence

Remidio compliance and trust

Trust signal

Compliance6 records

Remidio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Remidio leadership team

Management profile

Number of profiles

Profiles3 records

Remidio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Remidio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Remidio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remidio

What does Remidio do?

Remidio designs, manufactures, and sells portable, FDA-cleared ophthalmic imaging devices — including handheld fundus cameras, portable slit lamps, autorefractors, and corneal scanners — along with the Remidio Connect cloud-based teleophthalmology platform. Its products enable point-of-care retinal, anterior segment, refractive, and corneal imaging without dilation, with AI-assisted clinical decision support, and are sold to healthcare organizations such as primary care providers, home care agencies, emergency departments, rural/mission programs, and eye care specialists.

Is Remidio a public or private company?

Remidio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Remidio founded?

Remidio was founded in 2011. It employs 1 to 10 people.

Where is Remidio based?

Remidio is headquartered in Glen Allen, United States, in the North America region.

How does Remidio make money?

Three revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are cloud Platform and Software Services and enterprise/Telehealth Services.

Who are Remidio's main competitors?

Emerging players on record are Eyenuk and Digital Diagnostics (formerly IDx-DR). Direct peers are Topcon Healthcare, Nidek, Forus Health, Carl Zeiss Meditec, Heidelberg Engineering, Optomed and icare (formerly Centervue / Eidon). Canon Eye Care is listed as a broad incumbent.

Does Remidio have an API?

No public API is recorded for Remidio.

What industry is Remidio in?

Remidio's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAN, Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids), with a secondary code of HLALAGAL, Ophthalmology & Vision Telemedicine Platforms. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Eyes On EyecareRemidio's portable fundus camera offers point-of-care imagingIndian medtech company Remidio received FDA 510(k) clearance in December 2025 for its Fundus on Phone (FOP NM-10) handheld fundus camera, enabling U.S. commercial deployment of the portable retinal imaging device. Bill Gates featured the FDA-cleared device in a LinkedIn post, highlighting its ability to detect early signs of conditions like high blood pressure and gestational diabetes, and its potential to reduce stillbirths and improve maternal healthcare globally. The battery-powered, smartphone-based device captures high-resolution fundus images in under a minute and is designed for point-of-care use across routine screenings and urgent assessments.YahooU.S. AI-Driven Retinal Screening Device Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034The U.S. AI-Driven Retinal Screening Device Market was valued at USD 851.4 million in 2024 and is projected to grow at a CAGR of 11.7%, reaching USD 2.6 billion by 2034, driven by rising diabetic retinopathy prevalence, an aging population, and advancements in deep learning image recognition. The diabetic retinopathy segment generated USD 461.7 million in revenue in 2024, while hospitals held the largest market share at 50.6%, supported by high patient volumes and investment capacity. Key market players identified include Topcon Healthcare, Visionix, EYENUK, DIGITAL DIAGNOSTICS, AEYE Health, Notal Vision, iCare, Remidio, Evolucare, Optomed, and Forus Health.PR NewswireHealth-tech innovator Remidio achieves unprecedented scale in the US with its revolutionary retinal solutionsRemidio Inc., a health technology company specializing in retinal imaging devices, is placing its 1000th FOP-NM handheld fundus camera with US healthcare providers this quarter, having supported diabetic retinopathy screening for over 3,500 high-volume providers since 2019. The FOP-NM is the world's first smartphone-based non-mydriatic fundus camera, eliminating the need for patient dilation and enabling retinal exams by both specialists and non-specialists in various settings. The company aims to impact nearly 30 million people at risk for Diabetic Retinopathy in the US and is opening its hardware and telehealth platform for collaboration with AI SaMD companies and care providers.PR NewswireL'IA révolutionnaire de Remidio sur un smartphone pour la rétinopathie diabétique (RD) référençable reçoit l'approbation réglementaire de classe II de la certification MDR de l'UEIndian medtech company Remidio received CE marking approval under EU MDR Class II for its Medios AI system, which detects referable Diabetic Retinopathy using a smartphone-based fundus camera without requiring an internet connection.PR NewswireRemidio's Medios AI shows significant promise in last-mile Screening for Referable GlaucomaRemidio Inc, in partnership with Aravind Eye Hospital (AEH) in Pondicherry and Narayana Nethralaya (NN) in Bangalore, announced results from a landmark clinical trial of its Medios Referable Glaucoma AI solution, which combines a portable fundus imaging device with an offline AI algorithm for screening. The prospective study of 536 total subjects demonstrated high diagnostic performance, with sensitivity of 93.5% and specificity of 85.4% at NN, and sensitivity of 91.3% and specificity of 91.67% at AEH's Vision Centers, achieving comparable results in last-mile screening contexts as in tertiary care settings. The integrated system provides instant results in 15 seconds without requiring internet connectivity or specialist expertise, offering a deployable tool to address the global burden of 120 million expected glaucoma cases by 2040.